Eledon Pharmaceuticals (ELDN) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Eledon Pharmaceuticals (ELDN) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 38.1% versus a loss of 78.2%. Over five years, ELDN leads with a -58.1% price change compared with -98.1% for NBP. Eledon Pharmaceuticals is the larger company by market cap ($173.1 million vs $146.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELDN | NBP |
|---|---|---|
| Share price | $2.13 | $1.26 |
| Market cap | $173.09M | $146.16M |
| 1-day change | -6.17% | -2.33% |
| YTD return | +41.06% | -68.34% |
| 1-year return | -38.08% | -78.16% |
| 5-year return | -58.07% | -98.13% |
| EPS (TTM) | $-0.90 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-45.62M | $-46.27M |
| 52-week high | $4.60 | $5.97 |
| 52-week low | $1.35 | $1.26 |
| Distance from 52-week high | -53.70% | -78.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +322.54% | +614.29% |
| Average volume | 914.37K | 390.05K |
| Shares outstanding | 81.26M | 116.00M |
| Employees | 33 | 30 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELDN has outperformed NBP by 40.1 percentage points over the past year.
About Eledon Pharmaceuticals
ELDN stock →Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
Healthcare · Biotechnology · 33 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Healthcare · Biotechnology · 30 employees
ELDN vs NBP FAQ
Which is bigger, Eledon Pharmaceuticals or NovaBridge Biosciences?
Eledon Pharmaceuticals (ELDN) is larger, with a market capitalization of $173.09M compared with $146.16M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, ELDN or NBP?
ELDN returned -38.08% over the past 12 months, compared with -78.16% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are Eledon Pharmaceuticals and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.